These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
1982 results:

  • 1. A novel protein SPECC1-415aa encoded by N6-methyladenosine modified circSPECC1 regulates the sensitivity of glioblastoma to TMZ.
    Wei C; Peng D; Jing B; Wang B; Li Z; Yu R; Zhang S; Cai J; Zhang Z; Zhang J; Han L
    Cell Mol Biol Lett; 2024 Sep; 29(1):127. PubMed ID: 39333871
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.
    Cooksey LC; Friesen DC; Mangan ED; Mathew PA
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329751
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The Impact of Extensive Surgical Resection of Butterfly Glioblastomas on Outcomes in the Presence of TERT Mutation and egfr Amplification: A Retrospective Cohort Study.
    Hekimoglu M; Basak AT; Akgun MY; Ozer H; Ozgen U; Maleki R; Saban D; Oktenoğlu T; Ozer AF; Sasani M
    Cancer Control; 2024; 31():10732748241288121. PubMed ID: 39327682
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.
    van Opijnen MP; de Vos FYF; Cuppen E; Geurts M; Maas SLN; Broekman MLD
    Med Oncol; 2024 Sep; 41(11):250. PubMed ID: 39316248
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ.
    Sarkar S; Kumar S; Saha G; Basu M; Ghosh MK
    Int J Pharm; 2024 Nov; 665():124697. PubMed ID: 39270762
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
    Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K
    Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Chromosomal instability: a key driver in glioma pathogenesis and progression.
    Mazzoleni A; Awuah WA; Sanker V; Bharadwaj HR; Aderinto N; Tan JK; Huang HYR; Poornaselvan J; Shah MH; Atallah O; Tawfik A; Elmanzalawi MEAE; Ghozlan SH; Abdul-Rahman T; Moyondafoluwa JA; Alexiou A; Papadakis M
    Eur J Med Res; 2024 Sep; 29(1):451. PubMed ID: 39227895
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance.
    Hwang YK; Lee DH; Lee EC; Oh JS
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195222
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review).
    Cini NT; Pennisi M; Genc S; Spandidos DA; Falzone L; Mitsias PD; Tsatsakis A; Taghizadehghalehjoughi A
    Oncol Rep; 2024 Oct; 52(4):. PubMed ID: 39155859
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PTBP1-mediated repression of neuron-specific CDC42 splicing constitutes a genomic alteration-independent, developmentally conserved vulnerability in IDH-wildtype glioblastoma.
    Yang J; Feng J; Lv J; Chu X; Wei Y; Zhang Y; Li J; Sun Y; Li G; Jiang T; Huang J; Fan X
    Funct Integr Genomics; 2024 Aug; 24(4):135. PubMed ID: 39117866
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Kinetic Trajectories of Glucose Uptake in Single Cancer Cells Reveal a Drug-Induced Cell-State Change Within Hours of Drug Treatment.
    Kim J; Ng RH; Liang J; Johnson D; Shin YS; Chatziioannou AF; Phelps ME; Wei W; Levine RD; Heath JR
    J Phys Chem B; 2024 Aug; 128(33):7978-7986. PubMed ID: 39115241
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
    Guo G; Zhang Z; Zhang J; Wang D; Xu S; Liu G; Gao Y; Mei J; Yan Z; Zhao R; Wang M; Li T; Bu X
    Cancer Immunol Immunother; 2024 Aug; 73(10):193. PubMed ID: 39105794
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.
    Li N; Rodriguez JL; Yin Y; Logun MT; Zhang L; Yu S; Hicks KA; Zhang JV; Zhang L; Xie C; Wang J; Wang T; Xu J; Fraietta JA; Binder ZA; Lin Z; O'Rourke DM
    Mol Ther; 2024 Oct; 32(10):3522-3538. PubMed ID: 39086131
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
    Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
    Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Formation of egfrwt/egfrvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy.
    Jahnke K; Struve N; Hofmann D; Gote MJ; Bach M; Kriegs M; Hausmann M
    Nanoscale; 2024 Aug; 16(32):15240-15255. PubMed ID: 39073345
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Discovery of a Therapeutic Agent for Glioblastoma Using a Systems Biology-Based Drug Repositioning Approach.
    Kaynar A; Ozcan M; Li X; Turkez H; Zhang C; Uhlén M; Shoaie S; Mardinoglu A
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063109
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of
    Wichmann CW; Morgan KA; Cao Z; Osellame LD; Guo N; Gan H; Reilly E; Burvenich IJG; O'Keefe GJ; Donnelly PS; Scott AM
    J Nucl Med; 2024 Sep; 65(9):1456-1462. PubMed ID: 39054282
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A syngeneic spontaneous zebrafish model of
    Weiss A; D'Amata C; Pearson BJ; Hayes MN
    Elife; 2024 Jul; 13():. PubMed ID: 39052000
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.
    Tarabini RF; Fioravanti Vieira G; Rigo MM; de Souza APD
    Sci Rep; 2024 Jul; 14(1):16721. PubMed ID: 39030304
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Brain-Targeted Cas12a Ribonucleoprotein Nanocapsules Enable Synergetic Gene Co-Editing Leading to Potent Inhibition of Orthotopic Glioblastoma.
    Ruan W; Xu S; An Y; Cui Y; Liu Y; Wang Y; Ismail M; Liu Y; Zheng M
    Adv Sci (Weinh); 2024 Sep; 11(33):e2402178. PubMed ID: 38943253
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 100.